SERPASIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL is a small-molecule injectable approved in 1954 by Novartis for an unknown indication. As a legacy NDA product, it represents one of the earliest pharmaceutical approvals in the modern era.
LOE Approaching
As a product approaching loss of exclusivity with minimal current commercial data, the brand team is likely in maintenance or wind-down mode with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SERPASIL represents a legacy product with minimal new hiring signals and limited career development momentum. Roles associated with this product are primarily defensive, focused on managing market transitions and ensuring compliance rather than driving innovation or growth.
Brand ManagerCommercial Operations
Worked on SERPASIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.